Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung. (Q47699895)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

Saira Bahnu Mohamed Yousoof

25 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Pathmanathan Rajadurai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

N Mohamad

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

P Jayalakshmi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

C-K Liam

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

J-L Tan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

13 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Biomedical Science

25 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

176-180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

25 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Improving lung cancer survival; time to move on

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Lung cancer in Asian women-the environment and genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09674845.2017.1331520

10.1080/09674845.2017.1331520

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28705139%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference